Eli Lilly And Co vs First Trust NASDAQ Clean Edge Green Energy Idx Fd — how do they compare? Eli Lilly And Co trades at $1,163 (market cap $1.05T), while First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $53.03. The key difference: Eli Lilly And Co pays a 0.59% dividend while First Trust NASDAQ Clean Edge Green Energy Idx Fd pays none. Which is the better fit depends on your goals.
| LLY | QCLN | |
|---|---|---|
Market Cap | $1.05T | — |
Sector | Health | Sector/Thematic |
52-Week High | $1.24K | $68.47 |
52-Week Low | $625.65 | $34.31 |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,175.15, down 0.33% on the day, with a bullish technical signal and strong fundamental momentum. Revenue surged to $65.18B in 2025, with net income reaching $20.64B, and the company has beaten earnings estimates for three consecutive quarters. Recent news includes a lawsuit from Novo Nordisk over weight-loss drug advertising, but analyst sentiment remains overwhelmingly positive with a $1,380 consensus price target.
Outlook is supported by robust earnings growth and high profitability margins, but risks include competitive pressures and elevated valuation multiples. The stock's current price is near key resistance at $1,174, with institutional buying activity indicating continued confidence in Lilly's growth trajectory in the pharmaceutical sector.
QCLN trades at $51.25, down 1.9% with a bearish technical signal showing 17 sell indicators versus 3 buy signals. The ETF faces headwinds from regulatory uncertainty around renewable energy permits and supply chain pressures, though long-term growth prospects remain supported by rising data center energy demand and global clean energy investments. Technical analysis indicates strong resistance at $52-$56 with support at $48-$51.
The clean energy sector faces near-term policy risks but benefits from structural tailwinds. Investment appeal depends on resolution of US permit delays and China trade tensions, with current technical weakness suggesting cautious entry points may emerge near support levels for long-term positioning in the energy transition theme.
Trailing returns across standard periods
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.
Read more on QCLN →